US FDA And The Election: Watch The Center Directors

A change in leadership of the US FDA device center is taking place with an eye towards stability in the longer term, but the upcoming elections could lead to more disruptive personnel changes.

leadership change
The new US president could impact whether several center directors stay at the FDA. • Source: Shutterstock

A leadership change at the US Food and Drug Administration’s medical device center is intended to provide a relatively smooth transition, but also raises questions about the potential for more disruptive changes in the agency’s leadership team in the coming year.

More from US FDA

US Government Keeps Lights On But Pharma Priorities For PBM Reform, Rare Diseases Nixed

 

The FDA will stay open, but its rare disease priority review voucher program will wind down after not being renewed on 20 December. PBM reform and other industry priorities also were nixed at the last minute in an effort to avoid a government shutdown.

Class Dismissed: US FDA’s ‘Dean’ Bob Temple Retiring After 52 Years

 

Robert Temple, the US FDA’s most experienced drug regulator, is currently serving an emeritus role at the agency. The immediate impact of his departure will be mostly symbolic, but still unsettling.

US FDA Principal Deputy Commissioner Bumpus Leaving At Year’s End, Creating Leadership Void

 
• By 

Namandje Bumpus' departure means there is no obvious, internal candidate to serve as acting commissioner when President-elect Donald Trump takes office in January and the Senate works to confirm a new leader.

AstraZeneca Says Andexxa Will Not Convert To Full Approval, Quietly Reveals Complete Response

 

Whether the FDA will seek withdrawal of the anticoagulant-reversal agent or request additional confirmatory data is unclear.

More from Agency Leadership

Pediatric RSV Vaccine Research Should Resume Cautiously US FDA Advisers Say

 

A safety signal may be platform or even Moderna-specific, the Vaccines and Related Biological Products Advisory Committee said.

Pharma’s ‘Middleman’ Message Still Resonates With Trump

 

Some pharma industry CEOs appear to have done well in their meeting with President-elect Donald Trump and his health care team.

Former Senate Republican Health Leader Not Concerned About Anti-Pharma Stance of Trump’s HHS Appointees

 

Former Sen. Richard Burr suggested to the Pink Sheet that Trump’s HHS leadership picks will have less ability to enact their agendas than people expect.